Nicholas Investment Partners, LP Chinook Therapeutics, Inc. Transaction History

Nicholas Investment Partners, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	SELL	$18.66 - $38.58 $812,717 - $1.68 Million	-43,554 Reduced 4.48%	928,637 $35.7 Million
Q1 2023 May 11, 2023	BUY	$21.53 - $26.8 $7.09 Million - $8.83 Million	329,471 Added 51.26%	972,191 $22.5 Million
Q4 2022 Feb 10, 2023	BUY	$18.63 - $27.35 $1.4 Million - $2.06 Million	75,305 Added 13.27%	642,720 $16.8 Million
Q3 2022 Nov 14, 2022	BUY	$17.51 - $23.37 $307,493 - $410,400	17,561 Added 3.19%	567,415 $11.2 Million
Q2 2022 Aug 10, 2022	BUY	$12.59 - $18.8 $5.16 Million - $7.71 Million	410,036 Added 293.26%	549,854 $9.62 Million
Q1 2022 May 10, 2022	BUY	$12.02 - $16.69 $1.68 Million - $2.33 Million	139,818 New	139,818 $2.29 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Nicholas Investment Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Nicholas Investment Partners, LP with notifications on news.